Summary: Asthma remains the most prevalent allergic disease in Poland and worldwide. The cost of its treatment is a significant burden on patientsʼ and nationalsʼ budgets. In particular costs regarding exacerbations of the disease are high. Currently, GINA recommends adding tiotropium (LAMA) to the therapy in the 4th and 5th step of treatment for patients at the age of six and older, to the combination of ICS + LABA in medium and high dose in that order. It appears that results of newly published clinical trials of innovative single inhaler triple therapies IND/GLY/MF and BDP/FOR/GLY, demonstrating its superiority or non-inferiority towards currently used treatment strategies, and decisions made by EMA on registration of investigated drugs in asthma, should be included in next GINA revision. Condition aine qua non for the widespread availability of new drugs for Polish patients is making them reimbursed. It should be a priority of health policy for this disease.